Pyrrolo[2,3-d]pyrimidine compounds

Details Pyrrolo[2,3-d]pyrimidine compounds Pyrrolo[2,3-d]pyrimidine compounds

2005-11-08

2005-11-08

Berch, Mark L. (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

Reexamination Certificate

active

06962993

ABSTRACT:
A compound of the formulawherein R1, R2and R3are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.

REFERENCES:
patent: 3670079 (1972-06-01), Patanelli et al.
patent: 4456464 (1984-06-01), Lee et al.
patent: 4526608 (1985-07-01), Lee
patent: 4590282 (1986-05-01), Henrick
patent: 4879309 (1989-11-01), Doll et al.
patent: 4933339 (1990-06-01), Sharma
patent: 4997936 (1991-03-01), Christensen et al.
patent: 5134123 (1992-07-01), Branca et al.
patent: 5356903 (1994-10-01), Eissenstat et al.
patent: 5389509 (1995-02-01), Maskasky
patent: 5686457 (1997-11-01), Traxler et al.
patent: 6080747 (2000-06-01), Uckun et al.
patent: 6136595 (2000-10-01), Ihle et al.
patent: 6180636 (2001-01-01), Traxler et al.
patent: 6187552 (2001-02-01), Roberds et al.
patent: 6310063 (2001-10-01), Ge et al.
patent: 6506762 (2003-01-01), Horvath et al.
patent: 6552192 (2003-04-01), Hanus et al.
patent: 6610847 (2003-08-01), Blumenkopf et al.
patent: 6627754 (2003-09-01), Blumenkopf et al.
patent: 2001/0053782 (2001-12-01), Blumenkopf et al.
patent: 2002/0019526 (2002-02-01), Blumenkopf et al.
patent: 2003/0073719 (2003-04-01), Wilcox et al.
patent: 2004/0242600 (2004-12-01), Bold
patent: 2005/0038049 (2005-02-01), Ding et al.
patent: 0795556 (1997-09-01), None
patent: 0682027 (1997-10-01), None
patent: WO9519774 (1995-07-01), None
patent: WO9713771 (1995-10-01), None
patent: WO9802437 (1996-07-01), None
patent: WO9802438 (1996-07-01), None
patent: WO9640142 (1996-12-01), None
patent: WO9702262 (1997-01-01), None
patent: WO9702266 (1997-01-01), None
patent: WO9718212 (1997-05-01), None
patent: WO9727199 (1997-07-01), None
patent: WO9728161 (1997-08-01), None
patent: WO9732879 (1997-09-01), None
patent: WO9749706 (1997-12-01), None
patent: WO9807726 (1998-02-01), None
patent: WO9823613 (1998-06-01), None
patent: WO9833798 (1998-08-01), None
patent: WO9951599 (1999-10-01), None
patent: WO9961428 (1999-12-01), None
patent: WO0000202 (2000-01-01), None
patent: WO0010981 (2000-03-01), None
The MDAdvice.com entry for Asthma http://www.mdadvice.com/topics/asthma/info/1.htm downloaded from the Internet Mar. 5, 2003.
The Medline Medical Encyclopedia entry for Psoriasis http://www.nlm.nih.gov/medlineplus/ency/article/000434.htm downloaded from the Internet Mar. 5, 2003.
Illustrated Health Encyclopedia entry for Crohn's disease Prevention http://www.austin360.com/shared/health/adam/ency/article/000249prv.html downloaded from the Internet Mar. 5, 2003.
Columbia University College of P & S Complete Home Medical Guide entry for Arthritis PREVENTION http://cpmcnet.columbia.edu/texts/guide/hmg25_0006.html downloaded from the Internet Mar. 5, 2003.
Joseph B. Bolen, Annual Rev. Immunol. 15:37 1-404 (1997).
Baird, J. Leukocyte Biol. 63, 669 (1998).
Johnston et al.,Phosphorylation and activation of the Jak-3 Janus Kinase in response to Interleukin-2, Nature, 370, 151 (1994).
S. M. Russell, et al.,Interaction of IL-2Rβ and γc Chains with Jak1 and Jak3: Implications for XSCID and XCID, Science, 266, 1042 (1994).
J. N. Ihle,The Janus Protein Tyrosine Kinase Family and Its Role in Cytokine Signaling, Adv. Immunology, 60, 1, (1995).
J. N. Ihle,The Janus Protein Tyrosine Kinases in hematopoietic cytokine signaling, Semin. Immunology, 7, 247, (1995).
T. Musso, et al.,Regulation of JAK3 Expression in Human Monocytes: Phosphorylation in Response to Interleukings 2, 4, and 7, J. Exp. Med., 181, 1425 (1995).
R. A. Kirken, et al.,Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 Recruitment by a COOH-terminal region of the IL-2 receptor β-chain, Cytokine, 7 689, (1995).
M. G. Malabarba, et al.,Activation of JAK3, but not JAK1, is Critical to Interleukin-4(IL4)Stimulated Proliferation and Requires a Membrane-proximal Region of IL4 Receptor α, J. Biol. Chem., 270, 9630, (1995).
J. H. Hanke, B. A. Pollok, and P. S. Changelian,Role of tyrosine kinases in lymphocyte activation: Targets for drug intervention, Inflamm. Res., 44, 357, (1995).
E.E. Eynon, et al.,Disruption of Cytokine Signaling in Lymphoid Development: Unique Contributions of the Common Cytokine Gamma Chain and the JAK3 Kinase, J. Interferon Cytokine Res., 16, 677, (1996).
S. A. Oakes, et al.,Signaling via IL-2 and IL-4 in JAK#-Deficient Severe Combined Immunodeficiency Lymphocytes: JAK3-Dependent and Independent Pathways, Immunity, 5, 605 (1996).
L. D. Norangelo, et al,Severe Combined Immune Deficiency due to Defects of the JAK3 Tyrosine Kinase, Prog. Immunodeficiency, 6, 61, (1996).
D. C. Thomis, et al.,Peripheral Expression of JAK3 is Required to Maintain T Lymphocyte Function, J. Exp. Med., 185, 197, (1997).
B. H. Nelson, et al.,Requirement for an initial signal from the membrane-proximal region of the interleukin 2 receptor γc chain for Janus kinase activation leading to T cell proliferation, Proc. Natl. Acad. Sci. USA, 94, 1878, (1997).
K. D. Liu, et al.,JAK/STAT signaling by cytokine receptors, Curr. Opin. Immunol.
W. J. Leonard and J. J. O'Shea,JAKS and STATS: Biological Implications, Annu. Rev. Immunol., 16, 293, (1998).
F. Candotti, et al.,Severe combined immune deficiencies due to defects in the common γ chain-JAK3 signaling pathway, Springer Semin. Immuopathol., 19, 401, (1998).
R. Malaviya, et al.,Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis, J. Biol. Chem., 274, 27028 (1999).
D. C. Thomis, et al.,The Jak Family Tyrosine Kinase Jak3 is Required for IL-2 Synthesis by Naíve/Resting CD4′ T Cells, J. Immunol., 163, 5411 (1999).
E. Chen, et al.,Advances in Cytokine Signaling: The Role of Jaks and STATs, Transplantation Proc., 31, 1482, (1999).
R. Moriggi, et al.,Stat5 Activation is Uniquely Associated with Cytokine Signaling in Peripheral T Cells, Immunity, 11, 225 (1995).
L. H. Wang, et al.,JAK3, STAT, and MAPK Signaling Pathways as Novel Molecular Targets for the Tyrphostin AG-490 Regulation of IL-2-Mediated T Cell Response, J. Immunol., 162, 3897, (1999).
E. A. Sudbeck, et al.,Structure-based Design of Specific Inhibitors of Janus Kinase 3 as Apoptosis-inducing Antileukemic Agents, Clin. Cancer Res., 5, 1569, (1999).
F. M. Uckun, et al.,In Vivo Toxicity and Pharmacokinetic Features of the Janus Kinase 3 Inhibitor WHI-P131 [40(4′-Hydroxyphenyl)-Amino-6,7-Dimethosyquinazoline], Clin. Cancer Research, 5, 2954, (1999).
E. A. Sudbeck and F. M. Uckun,Recent Advances in JAK3 kinase inhibitors, IDrugs, 2, 1026, (1999).
R. Malaviya, et al.,Genetic and Biochemical Evidence for a Critical Role of Janus Kinase(JAK)-3 in Mast Cell-Mediated Type I Hypersensitivity Reactions, Biochem. Biophys., Res. Commun., 257, 807, (1999).
V. N. Trieu, et al.,A Specific Inhibitor of Janus Kinase-3 Increases Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis, Biochem. Biophys. Res. Commun., 267, 22, (2000).
X. C. Li, et. al.,Blocking the Common γ-Chain of Cytokine Receptors Induces T Cell Apoptosis and Long-Term Islet Allograft Survival, J. Immunol., 164, 1193 (2000).
R. Malaviya, et al.,Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3′,5′-Dibromo-4′hydroxyphenyl)amino-6,7-dimethoxyquinazoline(WHI-P97),J. Pharmacol. Exp. Ther., 295, 912 (2000).
S. Ghosh, et al.,4-[93-Bromo-4-hydroxypheynl)amino]6,7-dimethoxyquinazolin-1-ium chloride methanol solvate and 4-[(3-hydroxyphenyl)amino0-6,7-dimethoxy-1-quinazolinium chloride. Acta Crystallogr. C: Cryst. Struct. Commun., C57, 76 (2001).
E. A. Skudbeck, et al.An inhibitor of janus kinase 3: 4-(4-hydroxyphenylamino)-6,7-dimethoxyquinazolin-1-ium chloride, Acta Crystallogr., SectC: Cryst. Struct. Commun., C56, 1282 (2000).
Traxler, P. M., et al.,Protein tyrosine kinase inhibitors in cancer treatment, Exp. Opin. Ther. Patents, (1997), 7 (6): 571-588.
Traxler, P. M., et al.,4-(phenylamino)pyrrolopyrimidine: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase, J. Med. Chem., (1996), 39, 2285-2292.

Affiliated with

Also associated with

Rating

Pyrrolo[2,3-d]pyrimidine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolo[2,3-d]pyrimidine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo[2,3-d]pyrimidine compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3501121